Page 770 - Clinical Immunology_ Principles and Practice ( PDFDrive )

742 ParT Six Systemic Immune Diseases

As no effective treatment is currently available to treat patients 21. Vassiliou VA, Moyssakis I, Boki KA, Moutsopoulos HM. Is the heart
with SS, several medications and other non–drug-based modalities affected in primary Sjogren’s syndrome? An echocardiographic study.
are being studied. Currently, several clinical trials using agents Clin Exp Rheumatol 2008;26:109–12.
targeting IFN, interleukin-6 (IL-6), Toll-like receptors (TLRs), 22. Lin DF, Yan SM, Zhao Y, et al. Clinical and prognostic characteristics of
573 cases of primary Sjogren’s syndrome. Chin Med J 2010;123:3252–7.
and inhibition of T-cell stimulation are underway. Use of steroids 23. Atzeni F, Sarsi-Puttini P, Signorelllo MC, et al. New parameters for
locally in the salivary glands showed some promising initial identifying subclinical atherosclerosis in patients with primary Sjogren’s
results, which should be confirmed in independent studies. syndrome: a pilot study. Clin Exp Rheumatol 2014;32:361–8.
24. Sezis Demirci M, Karabulut G, Gungor O, et al. Is There an Increased
Please check your eBook at https://expertconsult.inkling.com/ Arterial Stiffness in Patients with Primary Sjogren’s Syndrome? Intern
for self-assessment questions. See inside cover for registration Med 2016;55:455–9.
details. 25. Valim V, Gerdts E, Jonsson R, et al. Atherosclerosis in Sjogren’s syndrome:
evidence, possible mechanisms and knowledge gaps. Clin Exp Rheumatol
2016;34:133–42.
REFERENCES 26. Houghton K, Maleson P, Cabral D, et al. Primary Sjogren’s syndrome in
children and adolescents: are proposed diagnostic criteria applicable? J
1. Venables PJ. Sjogren’s syndrome. Best Pract Res Clin Rheumatol Rheumatol 2005;32:2225–32.
2004;18:313–29. 27. Voulgarelis M, Moutsopoulos HM. Mucosa-associated lymphoid tissue
2. Skopouli FN, Moutsopoulos HM. Autoimmune epitheliitis: Sjogren’s lymphoma in Sjogren’s syndrome: risks, management, and prognosis.
syndrome. Clin Exp Rheumatol 1994;12:S9–11. Rheum Dis Clin North Am 2008;34:921–33, viii.
3. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjogren’s 28. Vitali C, Bombardien S, Jonsson R, et al. Classification criteria for
syndrome. Autoimmun Rev 2010;9:A305–10. Sjogren’s syndrome: a revised version of the European criteria proposed
4. Fox RI. Sjogren’s syndrome. Lancet 2005;366:321–31. by the American-European Consensus Group. Ann Rheum Dis
5. Scofield RH. Genetics of systemic lupus erythematosus and Sjogren’s 2002;61:554–8.
syndrome. Curr Opin Rheumatol 2009;21:448–53. 29. Cornec D, Saraux A, Cochener B, et al. Level of agreement between 2002
6. Burbelo PD, Ambatipudi K, Alevizos I. Genome-wide association studies American-European Consensus Group and 2012 American College of
in Sjogren’s syndrome: what do the genes tell us about disease Rheumatology classification criteria for Sjogren’s syndrome and reasons
pathogenesis? Autoimmun Rev 2014;13:756–61. for discrepancies. Arthritis Res Ther 2014;16:R74.
7. Lessard CJ, Adrianto I, Ice JA, et al. Variants at multiple loci implicated in 30. Hernandez-Molina G, Avila-Casado C, Nunez-Alvarez C, et al. Utility of
both innate and adaptive immune responses are associated with Sjögren’s the American-European Consensus Group and American College of
syndrome. Nat Genet 2013;45:1284–92. Rheumatology Classification Criteria for Sjogren’s syndrome in patients
8. Li Y, Zhang K, Chen H, et al. A genome-wide association study in Han with systemic autoimmune diseases in the clinical setting. Rheumatology
Chinese identifies a susceptibility locus for primary Sjogren’s syndrome at (Oxford) 2015;54:441–8.
7q11.23. Nat Genet 2013;45:1361–5. 31. Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European
9. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation Consensus Group Sjogren’s syndrome classification criteria to newly
and perpetuation of Sjogren’s syndrome. Nat Rev Rheumatol proposed American College of Rheumatology criteria in a large, carefully
2010;6:529–37. characterised sicca cohort. Ann Rheum Dis 2014;73:31–8.
10. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning 32. Gallo A, Baldini C, Teos L, et al. Emerging trends in Sjogren’s syndrome:
of anti-Ro and anti-La antibodies in primary Sjogren’s syndrome. basic and translational research. Clin Exp Rheumatol 2012;30:779–84.
Autoimmun Rev 2011;10:123–5. 33. Gallo A, Alevizos I. Isolation of circulating microRNA in saliva. Methods
11. Bowman SJ. Patient-reported outcomes including fatigue in primary Mol Biol 2013;1024:183–90.
Sjogren’s syndrome. Rheum Dis Clin North Am 2008;34:949–62, ix. 34. Michael A, Bajiracharya SD, Yuen PS, et al. Exosomes from human saliva
12. Aps JK, Martens LC. Review: the physiology of saliva and transfer of as a source of microRNA biomarkers. Oral Dis 2010;16:34–8.
drugs into saliva. Forensic Sci Int 2005;150:119–31. 35. Willams AE, Choi K, Chan AL, et al. Sjögren’s syndrome-associated
13. Humphrey SP, Williamson RT. A review of saliva: normal composition, microRNAs in CD14+ monocytes unveils targeted TGFβ signaling.
flow, and function. J Prosthet Dent 2001;85162–9. Arthritis Res Ther 2016;18:1–13.
14. Castro I, Sepulveda D, Cortes J, et al. Oral dryness in Sjogren’s syndrome 36. Alevizos I, Alexander S, Turner RJ, Illej GG. MicroRNA expression
patients. Not just a question of water. Autoimmun Rev 2013;12:567–74. profiles as biomarkers of minor salivary gland inflammation and
15. Chai J, Logigian EL. Neurological manifestations of primary Sjogren’s dysfunction in Sjogren’s syndrome. Arthritis Rheum 2011;63:535–44.
syndrome. Curr Opin Neurol 2010;23:509–13. 37. Cotrim AP, Alevizos I. Human and viral microRNA expression in Sjogren
16. Bejot Y, Osseby GV, Ben Salem D, et al. Bilateral optic neuropathy syndrome. J Rheumatol 2014;41:2102–3.
revealing Sjogren’s syndrome. Rev Neurol (Paris) 2008;164:1044–7. 38. Zero DT, Brennan MT, Daniels TE, et al. Clinical practice guidelines for
17. Park JH, Hwang J, Min JH, et al. Presence of anti-Ro/SSA antibody may oral management of Sjogren disease: dental caries prevention. J Am Dent
be associated with anti-aquaporin-4 antibody positivity in neuromyelitis Assoc 2016;147:295–305.
optica spectrum disorder. J Neurol Sci 2015;348:132–5. 39. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary
18. Qiao L, Luo Y, Zhang LL, et al. [The clinical characteristics of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452–60.
Sjogren syndrome with neuromyelitis optica]. Zhonghua Nei Ke Za Zhi 40. Papageorgiou A, Voulgarelis M, Tzioufas AG. Clinical picture, outcome
2013;52:745–8. and predictive factors of lymphoma in Sjögren syndrome. Autoimmun
19. Fox RI, Liu AY. Sjogren’s syndrome in dermatology. Clin Dermatol Rev 2015;14:641–9.
2006;24:393–413.
20. Hatron PY, et al. Pulmonary manifestations of Sjogren’s syndrome. Presse
Med 2011;40:e49–64.